WO2016191695A3 - Traitements d'infections intracellulaires strictes - Google Patents

Traitements d'infections intracellulaires strictes Download PDF

Info

Publication number
WO2016191695A3
WO2016191695A3 PCT/US2016/034686 US2016034686W WO2016191695A3 WO 2016191695 A3 WO2016191695 A3 WO 2016191695A3 US 2016034686 W US2016034686 W US 2016034686W WO 2016191695 A3 WO2016191695 A3 WO 2016191695A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatments
intracellular infections
obligately intracellular
infections
obligately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/034686
Other languages
English (en)
Other versions
WO2016191695A2 (fr
Inventor
Jere W. Mcbride
Tian Luo
Taslima T. LINA
Paige S. DUNPHY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of WO2016191695A2 publication Critical patent/WO2016191695A2/fr
Publication of WO2016191695A3 publication Critical patent/WO2016191695A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des procédés utilisés pour le traitement d'infections bactériennes, par exemple d'infections par bactéries intracellulaires strictes. Selon certains modes de réalisation, un inhibiteur de Wnt peut être administré à un sujet mammifère pour traiter l'ehrlichiose
PCT/US2016/034686 2015-05-28 2016-05-27 Traitements d'infections intracellulaires strictes Ceased WO2016191695A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562167669P 2015-05-28 2015-05-28
US62/167,669 2015-05-28

Publications (2)

Publication Number Publication Date
WO2016191695A2 WO2016191695A2 (fr) 2016-12-01
WO2016191695A3 true WO2016191695A3 (fr) 2017-01-05

Family

ID=56133065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/034686 Ceased WO2016191695A2 (fr) 2015-05-28 2016-05-27 Traitements d'infections intracellulaires strictes

Country Status (1)

Country Link
WO (1) WO2016191695A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
US20220117920A1 (en) * 2019-02-14 2022-04-21 University Of Kentucky Research Foundation N-Aryl Benzenesulfonamides as Protonophores for the Treatment of Cancers, Metabolic Diseases and Traumatic Brain Injury
CN112933066B (zh) * 2021-02-26 2023-05-02 河南省农业科学院 抑制剂kn-93抑制猪繁殖与呼吸综合征病毒体外感染的方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130323284A1 (en) * 2012-06-05 2013-12-05 Jazzya Investments USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130323284A1 (en) * 2012-06-05 2013-12-05 Jazzya Investments USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAI XIYUAN ET AL: "Inhibition of Nuclear Factor-Kappa B Activation Decreases Survival of Mycobacterium tuberculosis in Human Macrophages", PLOS ONE, vol. 8, no. 4, April 2013 (2013-04-01), XP055293629 *
DE GROOTE M A ET AL: "The Search For New Antimicrobial Agents Against Mycobacterium abscessus", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, 2012, & 52ND INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC); SAN FRANCISCO, CA, USA; SEPTEMBER 09 -12, 2012, pages F831, XP009191237, ISSN: 0733-6373 *
DUMLER J STEPHEN ET AL: "Ehrlichioses in humans: Epidemiology, clinical presentation, diagnosis, and treatment", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 45, no. Suppl. 1, 15 July 2007 (2007-07-15), pages S45 - S51, XP002498681, ISSN: 1058-4838, DOI: 10.1086/518146 *
FLORES R ET AL: "Chlamydia pneumoniae Inclusion Membrane Protein Cpn1027 Interacts with Caprin 2 Enhancing the Canonical Wnt Signaling Pathway", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 110, 2010, & 110TH GENERAL MEETING OF THE AMERICAN-SOCIETY-FOR-MICROBIOLOGY; SAN DIEGO, CA, USA; MAY 23 -27, 2010, pages B - 055, XP055293653, ISSN: 1060-2011 *
KESSLER MIRJANA ET AL: "Chlamydia trachomatis Disturbs Epithelial Tissue Homeostasis in Fallopian Tubes via Paracrine Wnt Signaling", AMERICAN JOURNAL OF PATHOLOGY, vol. 180, no. 1, January 2012 (2012-01-01), pages 186 - 198, XP055293648 *
LUO TIAN ET AL: "Ehrlichia chaffeensis Exploits Canonical and Noncanonical Host Wnt Signaling Pathways To Stimulate Phagocytosis and Promote Intracellular Survival", INFECTION AND IMMUNITY, vol. 84, no. 3, March 2016 (2016-03-01), pages 686 - 700, XP009191238 *
SENDIDE KHALID ET AL: "Cross-talk between CD14 and complement receptor 3 promotes phagocytosis of mycobacteria: Regulation by phosphatidylinositol 3-kinase and cytohesin-1", JOURNAL OF IMMUNOLOGY, vol. 174, no. 7, April 2005 (2005-04-01), pages 4210 - 4219, XP055293620, ISSN: 0022-1767 *
WAKEEL A ET AL: "New insights into molecular Ehrlichia chaffeensis-host interactions", MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 12, no. 5, 1 May 2010 (2010-05-01), pages 337 - 345, XP027011818, ISSN: 1286-4579, [retrieved on 20100129] *

Also Published As

Publication number Publication date
WO2016191695A2 (fr) 2016-12-01

Similar Documents

Publication Publication Date Title
WO2015114666A3 (fr) Traitements pour l'acné résistante
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
WO2013184755A3 (fr) Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation
MY173518A (en) Antimicrobial compounds and methods of making and using the same
WO2013122888A3 (fr) Méthodes de traitement d'infections bactériennes
WO2016179440A3 (fr) Thérapie antimicrobienne
PH12016502092A1 (en) Antimicrobial compounds and methods of making and using the same
WO2017083431A3 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
PH12016500453A1 (en) Antimicrobial compounds and methods of making and using the same
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
MX2013012165A (es) Composicion y metodo para mejorar una respuesta inmune.
WO2016210384A3 (fr) Bactéries manipulées pour traiter des maladies métaboliques
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MY176900A (en) Antimicrobial compounds and methods of making and using the same
MX2016010451A (es) Benzoxaboroles microbicidamente activos.
AU2015352440B2 (en) Compounds
EP3268010A4 (fr) Compositions et méthodes de traitement d'une infection bactérienne
MY161870A (en) Antimicrobial compounds and methods of making and using the same
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
EP3190893A4 (fr) Compositions et procédés de traitement et de prévention d'infections bactériennes
IN2013MU03216A (fr)
MX2016010057A (es) Compuestos antibacterianos.
WO2015035234A3 (fr) Composés et compositions antimicrobiens
EP3212183A4 (fr) Compositions synergiques pour le traitement d'infections microbiennes
WO2015044317A3 (fr) Inhibiteurs de staphylococcus haemolyticus pour la prévention et/ou le traitement de la dermatite atopique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16729696

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16729696

Country of ref document: EP

Kind code of ref document: A2